Back to results
US 2014/0213467 A1Published application
Mucin 5B as a Pancreatic Cyst Fluid Specific Biomarker for Accurate Diagnosis of Mucinous Cysts and Other Markers Useful for Detection of Pancreatic Malignancy
OwnerAnthony T. Yeunginventor
Life of this patent
Estimating the term…
Abstract
Compositions and methods which indicate an increased risk for pancreatic carcinoma in a test subject are disclosed.
Claims5
A method of differentiating a pancreatic mucinous cyst from a non-mucinous cyst in a human test subject, said method comprising:
- a) providing a pancreatic cyst fluid specimen from a human test subject;
- b) analyzing said fluid specimen for the presence or absence of mucin 5B in said cyst fluid sample, said presence being indicative of a mucinous cyst.
A method for predicting risk or classifying pancreatic cancer based on the presence or absence of pancreatic biomarkers in a fluid sample isolated from the pancreas of a subject or a tissue isolated therefrom in a patient in need thereof, said method comprising:
- a) providing a protein profile of the proteins present in said fluid sample;
- b) determining whether one, two, three or four or more of at least two proteins selected from the group consisting of Mucin-5B, Mucin-5AC, Mucin-1, Gelsolin, Carcinoembryonic antigen-related cell adhesion molecule 5 precursor, Ezrin Galectin-3-binding protein, Mucin-13, Leukocyte elastase inhibitor, Annexin A1, Annexin A2, Carcinoembryonic antigen-related cell adhesion molecule 6, Annexin A3, Annexin A4, Galectin-4, Annexin A5, Phosducin, Tetraspanin-8, Galectin-3, Neutrophil gelatinase-associated lipocalin, Anterior gradient protein 2 homolog, Protein S100-A11, Protein S100-A6, Protein S100-A8, and Protein S100-A9.
Dependencies are inferred from the claim text.